Protara Therapeutics, Inc.

NASDAQ:TARA

Biotechnology

Healthcare
$2.34 -1.27%

-$0.05 today

Market cap
$144.07M
Beta
1.45
P/E (TTM)
-2.7
EPS (TTM)
-$1.48
52W Low $2.77High $7.82

Volume 1.15M

Average 0.73M

TARA Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Protara Therapeutics, Inc.NASDAQ: TARA

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$364K, compared with $89K a year earlier.

Context

  • Accumulated OCI amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Accumulated OCI increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -509.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$364K-504.4% QoQ
Last fiscal yearDec 2025
$90K+4400.0% YoY
Year agoMar 2025
$89K-509.0% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-509.0%——
1 year+4400.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
90K USD
Year-over-year change
+4400.0%

Accumulated OCI vs competitors

How TARA compares with its peers on the latest reported figures

  • TARA's Mar 2026 Accumulated OCI of -$364K is the 9th highest of the 10 companies compared; the peer median is -$11K.
  • Its year-over-year change of -509.0% is the lowest of 7, against a peer median of -181.6%.
  • Accumulated OCI amounts to 0.2% of total assets for TARA, versus a peer median of 0.0%.
TARA Competitors Peer median
Accumulated OCI for TARA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SLSSELLAS Life Sciences Group, Inc.Sep 2026$0 ——0.0%
MDWDMediWound Ltd.Mar 2026$0 ——0.0%
NTHINeonc Technologies Holdings, Inc.Mar 2026$0 ——0.0%
OABIOmniAb, Inc.Mar 2026-$2K -125.0%+10.1%0.0%
CDXSCodexis, Inc.Mar 2026-$11K -178.6%—0.0%
IVVDInvivyd, Inc.Mar 2026-$37K -184.6%—0.0%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026-$40K -208.1%—0.0%
PRLDPrelude Therapeutics IncorporatedMar 2026-$41K -441.7%—0.0%
TARAProtara Therapeutics, Inc.Mar 2026-$364K -509.0%—0.2%
SGMOSangamo Therapeutics, Inc.Mar 2026-$2.51M +54.5%—4.2%
Peer median (excluding TARA) -$11K-181.6%+10.1%0.0%

Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents35.72M24.13M39.59M162.8M49.66M
Short-term Investments55.51M60.24M25.99M7.49M105.9M
Net Receivables634K486K242K01.26M
Inventory01.16M000
Other Current Assets34K(1.04M)37K2K65K
Total Current Assets93.11M86.15M68.71M172.16M159.5M
Property, Plant & Equipment (Net)8.89M7.87M6.56M5.28M3.93M
Goodwill29.52M0000
Intangible Assets084K2.66M3.25M2.93M
Long-term Investments39.47M17.89M0042.34M
Tax Assets00000
Other Non-current Assets1.61M1.31M1.03M772K765K
Total Non-current Assets79.48M27.14M10.25M9.3M49.96M
Total Assets172.6M113.29M78.95M181.45M209.47M
Account Payables954K1.59M2.43M4.43M3.47M
Short-term Debt00000
Tax Payables41K0000
Deferred Revenue00000
Other Current Liabilities1.8M2.54M2.11M2.53M3.27M
Total Current Liabilities4.3M5.74M6.15M10.96M10.94M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities6.38M5.47M4.48M3.36M2.12M
Total Liabilities10.68M11.21M10.63M14.32M13.06M
Common Stock11K11K11K35K54K
Retained Earnings(94.01M)(159.96M)(200.38M)(244.98M)(302.42M)
Accumulated OCI(211K)(688K)(31K)2K90K
Other Stockholders Equity00000
Minority Interest00000
Total Equity161.91M102.08M68.32M167.13M196.41M
Total Debt7.24M6.38M5.47M4.48M3.36M
Net Debt(28.49M)(17.74M)(34.12M)(158.32M)(46.3M)

Protara Therapeutics, Inc.

NASDAQ:TARA

Intrinsic Alpha fair value

Locked

Current Price

$2.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.